Latest News and Press Releases

HOLLISTON, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) has introduced SmartStudy™, an innovative technology feature to its Buxco® Inhalation System aimed at...

HOLLISTON, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for first quarter ended March 31, 2022 before the market opens on May...

Revenue up 7% year-over-year as sales momentum continues, despite global supply chain headwindsGross margin improves to 59% in Q4 driven by strengthening product mix, improved operating leverage ...

HOLLISTON, Mass., Feb. 21, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for fourth quarter ended December 31, 2021 before the market opens on...

Strong double digit revenue growth, solid margin performance despite global supply chain disruptions Revenue up 23% year-over-year as sales momentum continuesPre-clinical product revenue up...

HOLLISTON, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for third quarter ended September 30, 2021, before the market opens on...

Strong double digit revenue growth, solid margin performance despite global supply chain disruptions Revenue up 25% year-over-year as sales momentum continuesCellular and Molecular (CMT) product...

HOLLISTON, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for second quarter ended June 30, 2021 before the market opens on...

Sales effectiveness, pre-clinical product demand and disciplined cost management result in improved revenues and margins Revenue up 14% as sales momentum from Q4’20 continuesPre-clinical product...

HOLLISTON, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for first quarter ended March 31, 2021 before the market opens on May...